However, for other cancers, including immune subtypes such as BLCA, CHOL, ESCA, LGG, LIHC, SKCM, and USC, as well as molecular subtypes like GBM, the expression of C10orf90 is not statistically significant (Supplementary Figure S5). This evidence concerns the gene C10orf90 and glioblastoma.